Breo Launch Timing Slips But No “Drama,” GSK’s Witty Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The once-daily COPD medication Breo is an important launch for GSK, and the company has pushed back the timing by a few weeks, potentially into the fourth quarter, to make sure it is “nailed,” CEO Witty says during the company’s second quarter call. Nonetheless, Breo may be experiencing more pushback from payers than GSK expected.
You may also be interested in...
GSK’s Prices Breo On Par With Advair For COPD
The wholesale acquisition cost of GlaxoSmithKline’s once-daily COPD medication Breo is the same as Advair, reflecting the high reimbursement hurdle for new respiratory medicines.
COPD Market Snapshot: New Products, Limited Differentiation
New drugs are hitting the COPD market, but largely offer incremental benefit over gold standards Advair and Spiriva. Given the modest efficacy improvement and increasingly price sensitive patients and payers, new higher-priced products may find the commercial market a challenge.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.